Biomarker Solutions


Berlin Institute of Health (BIH) selects BioCog Consortium as a „pathfinder study“

The FP7 EU-funded BioCog Consortium (Biomarker Development for Postoperative Cognitive Impairment in the Elderly), which includes Pharmaimage GmbH as a major partner, has been selected by the Berlin Institute of Health (BIH) as a „pathfinder study“.

The BIH, which is funded by the Federal Government and the City of Berlin is a newly founded collaborative platform for translational research of the Charite – University Medicine Berlin and the Max-Delbrück Center for Molecular Medicine (Helmholtz Foundation):

Georg Winterer, Coordinator of the BioCog Consortium and CRO of Pharmaimage:

„Support from BIH is extremely helpful for the BioCog Consortium because it provides access to state-of-the art clinical research infrastructure for conducting large-scale clinical studies in a University Hospital setting. In addition, we will be able to extend our previous BioCog study protocol, now allowing additional microRNA array and metabolomic investigations.“

© PI-PharmaImage Germany GmbH 2017 | Webdesign: blickpunkt |x|, Köln